MAPK3 and lung adenocarcinoma: For both the entire sample and the individual squamous cell lungcancer and lung adenocarcinoma groups, there was a trend for patients whoresponded to immunotherapy to demonstrate higher ERK1/2 activation in tumorsamples (Fig. 6F-H).However, because the sample was small and the observed difference did not reach the level ofstatistical significance, this finding needs to be revisited in an independentanalysis using a larger cohort of patients.